Urinary tract infection caused by Enterococcus spp.: Risk factors and mortality. An observational study

Autor: Álvarez-Artero, E., Campo-Nuñez, A., García-García, I., García-Bravo, M., Cores-Calvo, O., Galindo-Pérez, I., Pendones-Ulerio, J., López-Bernus, A., Belhassen-García, M. ^*, Pardo-Lledías, J.

Publikováno v: In Revista Clínica Española (English Edition) August-September 2021 221(7):375-383

The updated Charlson comorbidity index is a useful predictor of mortality in patients with Staphylococcus aureus bacteraemia

Autor: Ternavasio-de la Vega, H. G., Castaño-Romero, F., Ragozzino, S., González, R. Sánchez, Vaquero-Herrero, M. P., Siller-Ruiz, M., Spalter-Glicberg, G., Ramírez-Baum, C., Rodríguez-Rodríguez, S., García-Sánchez, J. E., García-García, I., Marcos, M.

Publikováno v: Epidemiology and Infection, 2018 Dec 01. 146(16), 2122-2130.

Externí odkaz: https://www.jstor.org/stable/26579475

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.

Autor: García-García, I.¹ (AUTHOR), Guerra-García, P.^1,2,3 (AUTHOR), Ferreras, C.³ (AUTHOR), Borobia, A. M.^1,3,4 (AUTHOR), Carcas, A. J.^1,3,4 (AUTHOR), Queiruga-Parada, J.¹ (AUTHOR), Vicario, J. L.⁵ (AUTHOR), Mirones, I.² (AUTHOR), Solano, C.⁶ (AUTHOR), Eguizabal, C.^7,8 (AUTHOR), Soria, B.^9,10,11 (AUTHOR), Pérez-Martínez, A.^2,3,4 (AUTHOR) aperezmartinez@salud.madrid.org

Publikováno v: Trials. 10/2/2021, Vol. 22 Issue 1, p1-12. 12p. 1 Diagram, 3 Charts.

An approach for estimating the maximum specific growth rate of Gluconobacter japonicus in strawberry purée without cell concentration data

Autor: Cañete-Rodríguez, A.M., Santos-Dueñas, I.M., Jiménez-Hornero, J.E., Torija-Martínez, M.J., Mas, A., García-García, I.

Publikováno v: In Biochemical Engineering Journal 15 January 2016 105 Part A:314-320

Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines

Autor: García-Alfonso, Pilar, Saiz-Rodríguez, M., Mondéjar, R., Salazar, Juliana, Páez, David, Borobia, A. M., Safont, M. J., García-García, I., Colomer, Ramon, García-González, Xandra, Herrero Cervera, María José, López-Fernández, L. A., Abad-Santos, Francisco, Universitat Autònoma de Barcelona

Publikováno v: Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona

5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1957689f273a9bc35b561c8a3d356288
https://doi.org/10.1007/s12094-021-02708-4